A Phase III Multicenter Randomized Study of the Efficacy Safety and Pharmacokinetics of the Port Delivery System with Ranibizumab in Patients with Diabetic Retinopathy (Pavilion)
Brief description of study
The purpose of this study is to evaluate the effects, good or bad, of a drug called ranibizumab when it is delivered by an ocular (eye) implant (also known as the Port Delivery System with ranibizumab, or PDS) as treatment for diabetic retinopathy (DR) versus routine diagnostic vision tests, photographs of your eye, and eye examinations to monitor your DR. The current approved form of ranibizumab is delivered through regular monthly eye injections.
Clinical Study Identifier: s20-00295
ClinicalTrials.gov Identifier: NCT04503551
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
